To investigate whether the ALDOA/PLD1 axis has clinical significance for cancer patients, we performed the immunohistochemical (IHC) staining of ALDOA, PLD1, and PLD2 with specific antibodies in clinical lung cancer samples to validate these findings (Figure 7A and Supplementary Figure S7). This evidence concerns the gene PLD2 and lung cancer.